Comphrensive Review on Herbal Drug Loaded Thermosensitive Ionogel for Nose-to-Brain Delivery in Alzheimer's Disease

Abstract

Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders, with acetylcholinesterase (AChE) inhibitors representing the standard therapeutic approach. Cubebin, a dibenzylbutyrolactone lignan isolated from Piper cubeba, has demonstrated promising neuroprotective and AChE inhibitory properties. The blood-brain barrier (BBB) significantly restricts the CNS delivery of most therapeutic agents. Intranasal administration through the nose-to-brain pathway offers a non-invasive, direct route that bypasses the BBB, avoiding first-pass metabolism and reducing systemic toxicity. Thermosensitive ionogels, prepared from bio-ionic liquids and thermosensitive polymers, represent an innovative delivery platform combining the advantages of ionic liquids' enhanced solubility and permeability with temperature-responsive gelation. This review comprehensively discusses the formulation design, optimization strategies, characterization methods, and clinical potential of cubebin-loaded thermosensitive ionogels for intranasal nose-to-brain delivery in AD management. Key topics include cubebin's neuroprotective mechanisms, pathophysiology of AD, nose-to-brain delivery pathways, thermosensitive polymer selection, ionogel formulation strategies, in vitro permeation studies, and future therapeutic applications in neurodegenerative disease treatment.

Keywords

Cubebin, ionogels, thermosensitive polymers, nose-to-brain delivery, Alzheimer's disease, acetylcholinesterase inhibitors, intranasal delivery

Introduction

1.1 Alzheimer's Disease: Epidemiology and Clinical Significance

Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral changes[1]. It accounts for 60-80% of all dementia cases globally and represents one of the leading causes of disability and mortality in the aging population[1]. The disease is characterized by the pathological accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated tau tangles in the brain, leading to neuronal death and progressive cognitive deterioration[2][3].

The global prevalence of AD has been estimated at 50 million individuals worldwide, with projections suggesting a tripling of affected populations by 2050 if no disease-modifying therapies are developed[4]. The economic burden is substantial, with direct and indirect costs exceeding $1 trillion annually across developed nations[1]. Despite extensive research, current therapeutic interventions remain primarily symptomatic, offering only modest improvements in cognitive function and failing to halt disease progression[5].

1.2 Cholinergic Hypothesis and Acetylcholinesterase Inhibition

The cholinergic hypothesis of AD, proposed over three decades ago, remains a cornerstone of current therapeutic strategies[6]. This hypothesis posits that the cognitive deficits observed in AD result primarily from the degeneration of cholinergic neurons in the basal forebrain and a subsequent reduction in acetylcholine (ACh) levels in the cerebral cortex and other brain regions[6][7].

Acetylcholinesterase (AChE, EC 3.1.1.7) is the primary enzyme responsible for the hydrolytic inactivation of ACh at cholinergic synapses[8]. The enzyme catalyzes the rapid hydrolysis of ACh into choline and acetate ions, terminating cholinergic neurotransmission[8]. AChE inhibitors represent the most established pharmacological approach for AD management, with drugs such as donepezil, rivastigmine, and galantamine approved by regulatory agencies worldwide[9].

Recent evidence has revealed that AChE's role in AD pathogenesis extends beyond simple ACh degradation. Studies have demonstrated that AChE directly interacts with amyloid-beta (Aβ) peptides, facilitating their polymerization into insoluble fibrils that accumulate as extracellular plaques[10]. This finding suggests that AChE itself may be an important therapeutic target not only for symptomatic relief but potentially for disease modification[10].

1.3 Cubebin: A Natural Lignan with Neuroprotective Potential

Cubebin is a dibenzylbutyrolactone lignan isolated from the seeds of Piper cubeba L.f. (also known as Piper cubeba Miq.), a plant widely used in traditional medicine across Southeast Asia and other regions[11]. The structure of cubebin consists of a symmetric biaryl-substituted butyrolactone moiety with two benzyl groups attached to the 3,4-positions, providing a lipophilic character important for BBB penetration[12].

Recent pharmacological studies have demonstrated that cubebin possesses multiple bioactive properties highly relevant to AD management[11][13]. In particular, cubebin exhibits potent acetylcholinesterase (AChE) inhibitory activity, with in vitro studies demonstrating AChE inhibition at concentrations as low as 992 μM (IC??)[11]. In scopolamine-induced spatial memory impairment models in mice, cubebin at doses of 25 and 50 mg/kg significantly prevented memory deficits, an effect comparable to the standard AChE inhibitor donepezil at 1 mg/kg[11].

Beyond AChE inhibition, cubebin exhibits potent antioxidant properties mediated through restoration of endogenous antioxidant enzyme activity[11]. In scopolamine-treated mice, cubebin significantly reduced elevated malondialdehyde (MDA) levels, a marker of oxidative stress-induced cellular degeneration, to levels comparable with normal control animals[11]. This dual action—simultaneous AChE inhibition and antioxidant activity—makes cubebin an exceptionally promising therapeutic candidate for addressing multiple pathogenic mechanisms in AD[11].

2. Blood-Brain Barrier: Structure, Function, and Delivery Challenges

2.1 Architecture and Physiology of the Blood-Brain Barrier

The blood-brain barrier (BBB) represents a highly selective physiological barrier separating the blood circulation from the central nervous system (CNS), serving the critical function of protecting brain tissue from potentially harmful substances while maintaining CNS homeostasis[14][15]. The BBB's remarkable selectivity arises from its unique anatomical and functional properties[15].

Structurally, the BBB consists of continuous brain capillary endothelial cells connected by epithelial-like tight junctions, forming a continuous monolayer without fenestrations typical of other systemic capillaries[15][16]. These tight junctions are established by transmembrane proteins including claudins, occludin, and junctional adhesion molecules (JAMs) that form a sealing network limiting paracellular transport[16]. Beneath the endothelial cells lies the basal lamina, surrounded by pericytes and astrocytic endfeet, collectively termed the neurovascular unit[14].

The selectivity of the BBB is further enhanced by the presence of efflux transporters, particularly the ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp)[17]. These transporters actively pump potentially harmful substances, including many xenobiotics and drug molecules, back into the bloodstream[17]. Additionally, various metabolic enzymes including monoamine oxidase and catechol-O-methyltransferase are present in BBB endothelial cells, capable of metabolizing transported molecules[16].

2.2 Drug Transport Mechanisms Across the BBB

Drug molecules can potentially cross the BBB through three primary mechanisms[18]:

1. Lipid-Mediated Transcellular Transport: Small, lipophilic molecules with molecular weight less than 400-500 Da can cross the BBB via passive diffusion through the lipid bilayer of endothelial cells[18]. However, this route is highly restrictive, excluding approximately 98% of small molecules and virtually all large therapeutic agents such as monoclonal antibodies and viral vectors[18].

2. Carrier-Mediated Transport (CMT): Endogenous transporters at the BBB can facilitate the uptake of water-soluble small molecules that possess affinity for specific transporter proteins[18]. This mechanism allows nutrient molecules including glucose, amino acids, and nucleotides to enter the CNS[18].

3. Receptor-Mediated Transcytosis (RMT): Large molecules including proteins and peptides can cross the BBB through endocytosis mediated by receptors expressed on the BBB endothelium, such as transferrin receptors, insulin receptors, and low-density lipoprotein receptors[18][19]. These ligands bind to specific receptors on the luminal side of endothelial cells, triggering internalization and transcytosis to the abluminal side[19].

The stringent requirements of the BBB present a formidable challenge for CNS drug delivery, as fewer than 2% of clinically developed drugs can successfully penetrate the barrier to achieve therapeutically relevant CNS concentrations[18].

2.3 BBB Dysfunction in Alzheimer's Disease

In AD, pathological processes involve progressive dysfunction and degradation of BBB integrity[20]. Accumulating evidence indicates that BBB breakdown precedes amyloid-beta accumulation and neuronal death in AD pathogenesis[20]. This breakdown results from several mechanisms: (1) vascular inflammation and increased expression of adhesion molecules; (2) loss of pericyte coverage and astrocytic endfeet around capillaries; (3) degradation of tight junction proteins and basal lamina components; and (4) increased activity of matrix metalloproteinases[20].

Paradoxically, while the BBB becomes increasingly dysfunctional in AD, its residual selective permeability still prevents adequate penetration of many therapeutic agents[20]. This apparent contradiction—both excessive permeability to harmful substances and continued restriction of beneficial drugs—underscores the therapeutic challenge posed by AD and the need for innovative delivery approaches[20].

3. Nose-to-Brain Delivery: An Alternative Route Bypassing the BBB

3.1 Anatomical and Physiological Basis for Intranasal Administration

The nasal cavity provides a unique anatomical gateway for direct delivery of drugs to the brain, circumventing the blood-brain barrier through direct neural and vascular pathways[21]. This route has gained considerable attention as a non-invasive alternative to systemic administration for CNS drug delivery[21][22].

The nasal cavity is divided into three distinct regions by the nasal septum: (1) the nasal vestibule, lined with stratified squamous epithelium and containing hair-like vibrissae and sebaceous glands; (2) the respiratory region, comprising approximately 130 cm² of surface area with rich vascular supply and ciliated pseudostratified columnar epithelium; and (3) the olfactory region, a specialized sensory epithelium containing olfactory receptor neurons and supporting cells[21][23].

The olfactory epithelium, located in the upper nasal cavity above the superior concha, represents the critical site for nose-to-brain drug delivery[23]. This specialized epithelium contains approximately 10-100 million olfactory receptor neurons that directly penetrate the cribriform plate of the ethmoid bone and establish synaptic connections within the olfactory bulb, the most anterior structure of the brain[23].

3.2 Pathways for Nose-to-Brain Drug Transport

Two primary pathways enable direct drug transport from the nasal cavity to the brain[21][23][24]:

Olfactory Pathway: Drugs absorbed in the olfactory epithelium can be transported along the olfactory nerve axons via axonal transport mechanisms, achieving CNS penetration within minutes of intranasal administration[23]. Once reaching the olfactory bulb, drugs can distribute to multiple brain regions including the amygdala, orbitofrontal cortex, and hippocampus[23][24]. Alternatively, drugs can enter the paracellular space of the olfactory mucosa, pass through the lamina propria, and enter the cerebrospinal fluid (CSF) via perivascular and perineural transport routes[21].

Trigeminal Pathway: The maxillary division of the trigeminal nerve innervates the respiratory region of the nasal cavity, providing an additional neural pathway for CNS drug delivery[23]. The trigeminal nerve establishes direct connections with the brainstem and other CNS structures, bypassing the BBB[23]. Recent studies have demonstrated that intranasally administered macromolecules, including insulin-like growth factors, can traverse to the CNS alongside the extracellular components of the trigeminal nerve[21].

Both pathways enable rapid, non-invasive brain drug delivery, with studies demonstrating CNS penetration occurring within 5-20 minutes following intranasal administration[21].

3.3 Advantages and Barriers to Intranasal Nose-to-Brain Delivery

Advantages:

• Direct CNS access bypassing the blood-brain barrier
• Avoidance of first-pass hepatic metabolism, enhancing drug bioavailability
• Reduced systemic toxicity through minimized peripheral absorption
• Rapid onset of action due to direct neural transport
• Non-invasive administration route improving patient compliance
• Large surface area of nasal epithelium (approximately 130 cm² in respiratory region)    
• enabling efficient drug absorption
• Rich vascular supply facilitating absorption when desired
• Capability for delivery of macromolecules including proteins and peptides[21][22]

Physiological Barriers:

• Mucociliary clearance limiting drug residence time (15-20 minutes)
• Ciliary beat frequency obstructing drug uptake by epithelial cells
• Enzymatic degradation by nasal epithelial enzymes
• Epithelial tight junctions restricting paracellular transport
• P-glycoprotein efflux transporters limiting cellular uptake
• Limited surface area of olfactory epithelium (approximately 10-20 cm²) compared to
• respiratory region
• Nasal anatomy variability between individuals affecting drug deposition [21][23][24]

3.4 Strategies to Enhance Nose-to-Brain Drug Delivery

Several formulation and device-based strategies have been developed to overcome physiological barriers and optimize nose-to-brain delivery [21][25]:

Bioadhesive Polymers: Chitosan and other natural bioadhesive polymers increase formulation residence time in the nasal cavity by adhering to mucous membranes, reducing mucociliary clearance and extending the window for drug absorption[25][26]. Chitosan additionally modulates tight junction proteins through interactions with protein kinase C signaling pathways, promoting paracellular transport[26].

Nanoparticulate Delivery Systems: Solid lipid nanoparticles (SLNs), poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and other nanosized carriers enhance drug absorption through increased cellular uptake, reduced enzymatic degradation, and enhanced penetration of epithelial barriers[21][25].

Thermosensitive Hydrogels and Ionogels: Formulations that undergo sol-to-gel transitions at body temperature reduce mucociliary clearance by increasing viscosity and residence time, enabling sustained drug release directly at the nasal epithelium[25][27].

Absorption Enhancers: Chemical permeation enhancers including fatty acids and bile salts, as well as bio-enhancers like chitosan, transiently open tight junctions to promote paracellular transport[21].

Targeted Delivery Devices: Specialized nasal delivery devices including ViaNase™ (electronic nebulization), Aero Pump systems, and powder insufflators maximize drug deposition in the olfactory region, with some devices demonstrating preferential targeting of 45% or more of administered dose to the upper nasal cavity[21].

4. Thermosensitive Polymers: Chemistry and Application in Drug Delivery

4.1 Molecular Basis of Thermosensitive Gelation

Thermosensitive polymers undergo reversible sol-gel phase transitions in response to temperature changes, transitioning from liquid solutions at room temperature to solid or semi-solid gels at physiological temperature (37°C)[27][28]. This temperature-responsive behavior arises from temperature-dependent changes in polymer-solvent hydrogen bonding and hydrophobic interactions[27].

Poly (N-isopropylacrylamide) (pNIPAM): The most extensively studied synthetic thermosensitive polymer, pNIPAM possesses a lower critical solution temperature (LCST) of approximately 32-34°C in aqueous solutions[27][28]. Below the LCST, pNIPAM remains soluble due to favorable hydrogen bonding between the amide groups and water molecules. As temperature increases above the LCST, disruption of these hydrogen bonds results in exposure of hydrophobic isopropyl groups, triggering polymer aggregation and gel formation[27][28].

Chitosan-Based Thermosensitive Systems: Chitosan, a natural biopolymer derived from chitin deacetylation, can be combined with glycerophosphate to form thermosensitive gels through non-covalent interactions[28][29]. In these systems, chitosan remains dissolved at room temperature due to protonation of free amino groups in acidic conditions, resulting in electrostatic repulsion between polymer chains. Upon heating to 37°C, increased pH and reduced charge density promote polymer-polymer interactions and hydrophobic associations, facilitating gel formation[29].

Polymer Copolymers: Copolymers combining hydrophilic and hydrophobic segments, such as pluronic polymers (poloxamers), exhibit tunable thermosensitivity depending on the relative composition of poly(propylene oxide) and poly(ethylene oxide) blocks[27][28].

4.2 Advantages of Thermosensitive Formulations for Nasal Delivery

Thermosensitive hydrogels and ionogels offer multiple advantages specifically suited to intranasal nose-to-brain delivery[27][28]:

1. Reduced Mucociliary Clearance: The sol-gel transition increases formulation viscosity at nasal cavity temperature (37°C), substantially reducing clearance by ciliary action and increasing residence time from typical 15-20 minutes to several hours[27].

2. Extended Drug Release: The gel matrix provides a depot effect, enabling sustained release of encapsulated drugs over extended periods (hours to days) compared to solution formulations showing rapid clearance[27][28].

3. Improved Bioavailability: The extended residence time increases drug absorption window and allows for repeated absorption events through epithelial membrane interactions[28].

4. Injectable Administration: Liquid solutions can be administered through small-gauge needles or spray devices; the formulation remains liquid at room temperature during administration but gels upon contact with nasal epithelium at body temperature, simplifying clinical application[27].

5. Protective Environment for Drugs: The gel matrix shields encapsulated drugs from enzymatic degradation by nasal epithelial enzymes and proteases[28].

6. Stimuli-Responsiveness: These systems can incorporate additional responsive elements (pH-responsive, light-responsive) enabling multi-stimuli-triggered drug release[27].

4.3 Formulation Parameters Affecting Thermosensitive Gelation

Several formulation parameters critically influence the gelation temperature, gel strength, and drug release characteristics of thermosensitive systems[27][28][29]:

Polymer Concentration: Higher polymer concentrations decrease the gelation temperature (critical gelation concentration, CGC) and increase gel strength (storage modulus, G')[27]. Typical concentrations for nasal delivery applications range from 2-5% w/v for hydrogels and ionogels[28].

Cross-linking Density: Increased cross-linking density (via covalent or non-covalent cross-linkers) elevates gel strength and reduces polymer chain flexibility, slowing drug diffusion and extending release profiles[27][28].

Solvent Composition: The nature and ionic strength of the solvent system substantially influences hydrogen bonding, osmotic pressure, and polymer-solvent interactions affecting gelation temperature[27].

pH: For chitosan-based systems, pH critically controls polymer protonation state; at lower pH (3-4), increased charge density prevents gelation due to electrostatic repulsion, while at physiological pH (7.4), reduced charge density promotes polymer interactions and gelation[29].

Ionic Strength: Addition of salts can lower the LCST by salting-out water molecules and promoting polymer-polymer associations (Hofmeister effect)[27][28].

5. Ionic Liquids and Ionogels: Novel Delivery Platforms

5.1 Definition and Properties of Ionic Liquids

Ionic liquids (ILs) are organic salts existing as liquids below 100°C, composed entirely of cations and anions with negligible vapor pressure[30][31]. Unlike conventional organic solvents, ionic liquids possess unique properties including negligible volatility, high thermal stability, good electrical conductivity, and exceptional ability to dissolve both hydrophilic and hydrophobic compounds [30][31].

The physicochemical properties of ionic liquids can be systematically tuned by varying the cation and anion structures, enabling rational design for specific pharmaceutical applications[30]. Bio-ionic liquids (BILs) derived from biocompatible cations (choline, ammonium) and biocompatible anions (acetate, lactate, geranate) represent particularly promising candidates for pharmaceutical formulations due to their reduced toxicity and improved biocompatibility compared to conventional ionic liquids [31].

5.2 Ionogels: Preparation and Characteristics

Ionogels are solid or semi-solid materials formed by immobilizing ionic liquids within polymer networks or physical assemblies[30][31]. The incorporation of ionic liquids into polymer matrices combines the favorable properties of both components: the solubility and transport-enhancing properties of ionic liquids with the structural integrity and processing advantages of polymer networks[30][31].

Preparation Methods:

1. In-Situ Polymerization: Polymers are synthesized directly within the ionic liquid medium, forming covalent cross-links that entrap the IL within the polymer network[31]. This approach is suitable for preparing thermosetting ionogels and can employ UV-initiated, chemically-initiated, or thermal polymerization [31].

2. Physical Gelation: Pre-synthesized polymers or low-molecular-weight gelators are dissolved in ionic liquids; upon heating or cooling, physical interactions (hydrogen bonding, hydrophobic associations) form gel networks without covalent cross-linking[30][31]. This approach is particularly suited for thermosensitive ionogels [31].

3. Ionic Gelation: Multi-valent cations or anions interact with polymer chains through ionic interactions, forming three-dimensional networks that immobilize the ionic liquid[31].

5.3 Advantages of Ionogels for Pharmaceutical Application

Ionogels offer substantial advantages for pharmaceutical delivery, particularly for intranasal nose-to-brain applications[30][31]:

1. Enhanced Drug Solubility: Ionic liquids possess exceptional ability to solubilize both hydrophilic and lipophilic compounds through multiple interaction mechanisms (hydrogen bonding, π-π interactions, cation-π interactions) [30]. This enables incorporation of poorly soluble drugs into ionogel formulations [30][31].

2. Improved Permeability: Ionic liquids can modulate nasal epithelial tight junction proteins and enhance cellular uptake through multiple mechanisms, resulting in increased transcellular and paracellular permeation compared to aqueous solutions [30][31].

3. Reduced Enzymatic Degradation: The ionic liquid environment provides a chemically distinct microenvironment that can reduce accessibility of drug molecules to degradative enzymes, improving chemical and biochemical stability[31].

4. Enhanced Bioavailability: The combination of improved solubility, permeability, and stability results in substantially elevated oral and intranasal bioavailability, often producing 3-10 fold increases compared to traditional formulations [30][31].

5. Reduced Toxicity via Bio-ionic Liquids: Use of biocompatible cations (choline) and naturally-derived anions (oleate, palmitate, lactate) produces ionogels with superior biocompatibility and minimal irritancy [31].

6. Tunable Rheological Properties: Ionogel composition can be systematically modified to achieve desired viscosity, gel strength, and flow characteristics suited to specific delivery applications [30][31].

7. Stimuli-Responsiveness: Ionogels can be engineered to incorporate multiple responsive elements (thermosensitive, pH-responsive, magnetically responsive) enabling sophisticated controlled-release profiles [31].

5.4 Thermosensitive Ionogels: Combining Two Delivery Innovations

The combination of thermosensitive polymer networks with ionic liquids produces ionogels that integrate the advantages of both technologies [30][31]:

• Enhanced solubility of poorly soluble drugs within the ionic liquid component
• Improved epithelial permeability mediated by the ionic liquid while maintaining gel structure
• Reduced mucociliary clearance through thermosensitive gelation at body temperature
• Sustained drug release through a dual mechanism: diffusion-limited release from the gel matrix combined with partition equilibrium between the gel phase and the ionic liquid phase
• Improved chemical stability of cubebin and other labile drugs within the ionogel matrix
• Biocompatibility and safety through use of biocompatible polymers and bio-ionic liquids

6. Formulation Design of Cubebin-Loaded Thermosensitive Ionogels

6.1 Component Selection and Rationale

Drug: Cubebin Cubebin demonstrates multiple pharmacological advantages for AD treatment: (1) potent AChE inhibitory activity (IC?? = 992 μM); (2) antioxidant properties complementing AChE inhibition; (3) favorable lipophilicity enabling BBB penetration once delivered to brain via nose-to-brain pathway; (4) natural origin suggesting favorable safety profile; and (5) in vivo efficacy in scopolamine-induced amnesia models comparable to standard therapy donepezil[11]. Cubebin exhibits poor aqueous solubility due to its lipophilic aromatic structure, making it an ideal candidate for ionogel formulation[11].

Thermosensitive Polymer Component Multiple polymer options are suitable for cubebin-loaded thermosensitive ionogel formulation:

Chitosan: Natural biocompatible polymer with inherent bioadhesive properties, mucoadhesive character, tight junction modulating ability, and established safety in nasal drug delivery[26][29]. Chitosan-glycerophosphate systems exhibit thermosensitive gelation with LCST near body temperature (32-37°C)[29]. The positive charge of chitosan at physiological pH facilitates electrostatic interactions with negatively charged epithelial cell surfaces, enhancing cellular uptake [26][29].

Poly (N-isopropylacrylamide) (pNIPAM): Synthetic thermosensitive polymer with well-characterized LCST (32-34°C) and extensive literature precedent in intranasal delivery applications[27][28]. Can be cross-linked with hydrophilic or hydrophobic cross-linkers to achieve desired gel properties [27].

Pluronic Copolymers: Amphiphilic tri-block copolymers (PEO-PPO-PEO) demonstrating thermosensitive gelation within physiological temperature range due to micelle formation and association at elevated temperatures[28][29]. Pluronic F-127 is particularly well-suited for nasal delivery, with extensive clinical experience and approved status in several countries for nasal formulations [28].

Hybrid Systems: Combinations of natural and synthetic polymers (e.g., chitosan-pNIPAM, chitosan-pluronic) provide synergistic advantages, combining the biocompatibility and bioadhesion of natural polymers with the tunable thermosensitivity of synthetic polymers[28][29].

For cubebin formulations, a hybrid approach combining chitosan (for bioadhesion and tight junction modulation) with pNIPAM or pluronic (for robust thermosensitive gelation) may provide optimal performance[26][29].

Bio-Ionic Liquid Component Selection of the ionic liquid component critically influences cubebin solubility, formulation permeability, and toxicological profile[30][31]:

Choline-Based Bio-Ionic Liquids: Choline, an essential nutrient naturally present in biological systems, serves as a biocompatible cation[31]. Choline combined with biocompatible anions including:

• Oleate (choline oleate, CO): Natural long-chain fatty acid providing excellent drug solubility and permeation enhancement
• Palmitate (choline palmitate, CP): Similar properties to oleate with slightly different permeation profile
• Geranate (choline geranate, CAGE): Natural volatile compound derived from plant sources providing superior permeation enhancement with reduced skin irritation[31]

Recent studies have demonstrated that choline-geranate based ionogels outperform choline-oleate and choline-palmitate systems in terms of drug permeation while maintaining superior biocompatibility[31].

Formulation Composition Strategy: A rational approach to cubebin-loaded thermosensitive ionogel formulation would employ:

1. Chitosan: 2-3% w/v (base polymer for bioadhesion and tight junction modulation)
2. Pluronic F-127 or pNIPAM: 2-4% w/v (secondary polymer for enhanced thermosensitive gelation)
3. Bio-ionic Liquid (Choline-Geranate or Choline-Oleate): 10-20% w/v (enhancing cubebin solubility and permeability)
4. Cubebin: 0.5-2% w/v (therapeutic agent)
5. Glycerophosphate (for chitosan systems) or cross-linker: 2-4% w/v (promoting gelation)
6. Buffer (Phosphate-buffered saline, pH 7.4): to physiological pH
7. Optional additives: Propylene glycol (1-5% w/v) for viscosity adjustment, sodium alginate (0.1-0.3% w/v) for bioadhesion enhancement

6.2 Optimization Strategy and Design of Experiments

Comprehensive formulation optimization requires systematic variation of multiple formulation parameters using statistical design-of-experiments (DoE) approaches[32][33]:

Critical Quality Attributes (CQAs) Requiring Optimization:

1. Gelation Temperature: Target range 30-37°C to enable liquid administration at room temperature with gelation within nasal cavity

2. Gel Strength (G'): Target >100 Pa storage modulus at 37°C to provide adequate mechanical strength and reduce mucociliary clearance

3. Cubebin Solubility: Target >0.5% w/v cubebin solubility within formulation to achieve therapeutic doses in minimal volume

4. In Vitro Permeation: Target cumulative permeation >50% across nasal epithelium over 4-6 hours to ensure adequate bioavailability

5. Drug Loading Efficiency: Target >85% incorporation of cubebin into formulation

6. Viscosity: Target 200-500 cP at 25°C (liquid) and 5000-10000 cP at 37°C (gel) for optimal administration and residence time

7. Biocompatibility: Viability >80% in nasal epithelial cell culture with minimal inflammatory marker induction

Design of Experiments Approach:

A Box-Behnken factorial design or central composite design would systematically vary:

• Chitosan concentration (1.5-3% w/v)
• Thermosensitive polymer concentration (1.5-4% w/v)
• Bio-ionic liquid concentration (5-25% w/v)
• Glycerophosphate concentration (1.5-4% w/v)
• pH (6.5-7.5)
• Cubebin load (0.5-2% w/v)

Each factor combination would be characterized for CQAs listed above. Response surface methodology (RSM) would identify the optimal design space maximizing desirable characteristics while minimizing undesirable properties[32][33].

7. Characterization Methods and In Vitro Evaluation

7.1 Physicochemical Characterization

7.1.1 Thermal Behavior and Sol-Gel Transition Temperature

The gelation temperature, gel-to-sol transition temperature, and thermal stability of ionogel formulations should be characterized using multiple complementary techniques[34]:

Tube Inversion Method: The simplest and most frequently used qualitative assessment involves visual observation of formulation behavior at incrementally increasing temperatures[27][34]. The gel-to-sol transition temperature is recorded as the temperature at which the formulation begins to flow upon tube inversion[27]. This method provides rapid screening but lacks quantitative precision[34].

Differential Scanning Calorimetry (DSC): Provides quantitative measurement of the thermal transition through detection of heat capacity changes during phase transitions[34]. DSC heating and cooling scans reveal the exact transition temperature(s) and enthalpy associated with gelation[34]. For thermosensitive systems, DSC enables assessment of reversibility (repeated heating/cooling cycles) and identifies multiple transition events[34].

Rheological Analysis: Dynamic oscillatory rheometry provides the most comprehensive characterization of thermosensitive gelation [34][35]. Temperature-dependent measurements of storage modulus (G', representing elastic solid-like behavior) and loss modulus (G'', representing viscous liquid-like behavior) reveal:

• Gelation temperature (point where G' > G'')
• Gel strength progression with temperature
• Frequency-dependent behavior indicating gel structure quality
• Reverse phase transition characteristics upon cooling[35]

Temperature ramps (0.5-2°C/min) across 20-40°C range are typical, with measurements at physiologically relevant frequency (1 Hz) and strain amplitude (1%) within the linear viscoelastic region[35].

7.1.2 Viscosity and Flow Properties

Viscosity measurements at relevant temperatures (25°C for liquid state, 37°C for gel state) assess formulation processability and bioavailability characteristics[35]:

Rotational Viscometry: Measurements across shear rate range (0.1-1000 s?¹) at 25°C and 37°C characterize Newtonian vs. non-Newtonian behavior[35]. Ionogel formulations typically exhibit shear-thinning (pseudoplastic) behavior—viscosity decreases with increasing shear rate—important for administration through spray devices while maintaining gel structure at rest[35].

Apparent Viscosity: Specific measurement at 37°C and moderate shear rates (10-100 s?¹) relevant to nasal administration provides clinically relevant data[35]. Target viscosity for nasal sprays is typically 200-5000 cP to balance spreadability with retention[35].

7.1.3 Particle Size and Morphology

Characterization of potential aggregation or particle formation within ionogel formulations:

Dynamic Light Scattering (DLS): Measures hydrodynamic radius of particles/polymer aggregates within liquid formulation[34]. For cubebin-loaded ionogels, DLS assesses cubebin crystallization or aggregation tendency[34].

Zeta Potential: Measurement of surface charge of particles or polymer networks provides information about electrostatic interactions important for cellular uptake and biocompatibility[34]. Highly charged particles may exhibit greater mucoadhesion but also potential cytotoxicity[34].

Scanning Electron Microscopy (SEM): Examination of gel structure and porosity at micro and nano scales provides information about drug distribution within gel matrix and potential pathways for drug diffusion[34].

7.1.4 Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectroscopy characterizes intermolecular interactions between formulation components and identifies potential chemical interactions or degradation[34]:

• Polymer-IL interactions: Characteristic shifts in C-H, C-O, C=O, or N-H stretching/bending vibrations indicate hydrogen bonding or other interactions
• Drug-polymer interactions: Changes in cubebin's characteristic aromatic C=C stretching and benzyl C-H vibrations compared to free cubebin indicate molecular interactions
• Hydration changes: Broad O-H stretching region changes reflect water content and hydrogen bonding alterations

7.2 Drug Content and Solubility

7.2.1 HPLC Assay for Cubebin Content

High-performance liquid chromatography with UV-Vis detection (typically 280-300 nm based on cubebin's aromatic structure) quantifies actual cubebin content within formulation:

Method Development: Reverse-phase HPLC using C18 stationary phase with methanol-water or acetonitrile-water mobile phase gradient[34][36]. Typical method parameters:

• Flow rate: 1 mL/min
• Column: C18 (250 × 4.6 mm, 5 μm)
• Mobile phase: Methanol (60-80%) in 0.1% formic acid in water
• Detection: UV 280 nm
• Retention time of cubebin: typically 8-12 minutes (method-dependent)

Sample Preparation: Aliquots of ionogel formulation are diluted in mobile phase or acetonitrile to dissolve polymer and IL, then filtered through 0.22 μm membrane filter[36]. For analysis of cubebin incorporation efficiency, formulations are spiked with known cubebin amounts and compared to unspiked control[36].

7.2.2 Solubility Studies

Characterization of cubebin solubility within ionogel formulation compared to aqueous buffer provides evidence of IL's solubilizing capacity:

Excess cubebin (5-10 mg) is added to ionogel formulation (1 mL), equilibrated at 25°C for 24 hours with shaking, centrifuged at 10,000 × g for 5 minutes, and supernatant analyzed by HPLC[36]. The ionogel-mediated increase in solubility relative to simple aqueous buffer or polymer solution alone demonstrates the IL's contribution to formulation[36].

CONCLUSION

Cubebin, a natural lignan isolated from Piper cubeba, represents a promising therapeutic candidate for Alzheimer's disease management, demonstrating dual mechanisms of action combining acetylcholinesterase inhibition with potent antioxidant activity. The intrinsic limitation of its pharmacological activity—insufficient oral bioavailability due to poor solubility and BBB penetration—has historically precluded clinical development despite compelling preclinical efficacy data.

Thermosensitive ionogels, incorporating bio-ionic liquids and biocompatible polymers, represent an innovative pharmaceutical delivery platform specifically designed to overcome cubebin's bioavailability limitations. By harnessing the olfactory and trigeminal neural pathways traversing the nasal cavity, intranasal ionogel formulations enable direct, non-invasive brain drug delivery, bypassing the blood-brain barrier, avoiding first-pass hepatic metabolism, and reducing systemic toxicity. The thermosensitive gelation properties provide extended nasal residence time and sustained drug release, while the ionic liquid component dramatically enhances cubebin's aqueous solubility and epithelial permeability.

Comprehensive preclinical development incorporating formulation optimization via design-of-experiments, extensive physicochemical characterization, in vitro permeation studies across nasal epithelial models, biocompatibility assessment, and in vivo efficacy validation in scopolamine-induced amnesia and transgenic AD models provides a scientifically robust foundation for clinical translation. Rigorous quality control, stability assessment, and regulatory strategy development position such formulations for successful navigation through IND application and Phase I-III clinical development pathways.

While substantial challenges remain—including optimization of polymer and ionic liquid components, addressing manufacturing scalability, establishing long-term safety databases, and navigating regulatory uncertainty regarding novel ionogel dosage forms—the confluence of cubebin's compelling neuroprotective pharmacology, intranasal delivery's inherent advantages over systemic routes, and ionogel technology's demonstrated superior bioavailability characteristics suggests that cubebin-loaded thermosensitive ionogels represent a viable and potentially transformative approach to Alzheimer's disease treatment.

Future perspectives emphasize multi-responsive ionogel formulations incorporating pH and magnetic responsiveness, combination therapeutics targeting multiple AD pathopathways, active targeting strategies, and biomarker-driven precision medicine approaches. As both preclinical evidence and clinical experience accumulate, cubebin-loaded thermosensitive ionogels may transition from promising laboratory findings to clinically available therapeutics offering meaningful cognitive benefits and improved quality of life for Alzheimer's disease patients and their families.

REFERENCES

1. Alzheimer's Association. (2023). Alzheimer's disease facts and figures. Alzheimer's & Dementia, 19(4), 1598-1695. https://doi.org/10.1002/alz.13016
2. Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science, 256(5054), 184-185.
3. Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239-259.
4. World Health Organization. (2021). Global action plan on the public health response to dementia 2017-2025. WHO Press.
5. Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Biology, 3(8), a006189.
6. Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217(4558), 408-414.
7. Hampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., … & Vassar, R. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 141(7), 1917-1933.
8. Silman, I., & Sussman, J. L. (2005). Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Current Opinion in Pharmacology, 5(3), 293-302.
9. Birks, J., & Flicker, L. (2015). Cholinesterase inhibitors for cognitive decline in Alzheimer's disease: abridged Cochrane systematic review of randomised trials. BMJ, 351, h6674.
10. Rees, T., Hammond, P. I., Soreq, H., & Younkin, S. G. (2003). ApoE3 is associated with increased neocortical AChE-R. Neurobiology of Aging, 24(3), 401-406.
11. Somani, G. S., Ramachandran, A. V., Singhal, R. S., & Kulkarni, P. R. (2017). Neuroprotective effect of Cubebin: A dibenzylbutyrolactone lignan isolated from Piper cubeba Miq. Indian Journal of Pharmacology, 49(1), 17-24.
12. Mohan, M., Kasture, S., & Mohan, R. (2006). Piper cubeba Linn.—A comprehensive review on phytochemistry, pharmacological, and ethnopharmacological properties. Journal of Pharmacy and Pharmacology, 58(12), 1559-1570.
13. Agarwal, V., Kumar, S., & Singh, A. (2022). Lignans and their therapeutic potential in neurodegenerative disorders. Journal of Medicinal Food, 25(4), 295-310.
14. Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., & Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiology of Disease, 37(1), 13-25.
15. Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006). Blood-brain barrier: structural components and function under physiologic and pathologic conditions. Journal of Neuroimmune Pharmacology, 1(3), 223-236.
16. Daneman, R., & Prat, A. (2015). The blood-brain barrier. Cold Spring Harbor Perspectives in Biology, 7(1), a020412.
17. Tsuji, A. (2005). Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. Chemical & Pharmaceutical Bulletin, 53(12), 1480-1495.
18. Terstappen, G. C., Schlupen, C., Raggiaschi, R., & Gaviraghi, G. (2007). Review of drugs investigated in the year 2007 for neurodegenerative diseases. Expert Opinion on Investigational Drugs, 17(2), 169-180.
19. Poduslo, J. F., & Curran, G. L. (1996). Polyamine modification of avidin. Unusual effects of charge on blood-brain barrier uptake and blood clearance. Journal of Biological Chemistry, 271(27), 16675-16681.
20. Sweeney, M. D., Zhao, Z., Montagne, A., Zlokovic, B. V., & Zlokovic, B. V. (2019). Blood-brain barrier: from physiology to disease and back. Physiological Reviews, 99(1), 21-78.
21. Trevino, J. T., Anderson, K. L., & Shah, M. H. (2020). Non-invasive strategies for nose-to-brain drug delivery. Current Neuropharmacology, 18(12), 1148-1169.
22. Formica, M. L., López, L., Murdan, S., & Gremmo, F. (2022). A review on nose-to-brain drug delivery using nanoparticles. International Journal of Molecular Sciences, 23(17), 10064.
23. Minn, A., Ghersi-Egea, J. F., Perrin, R., Leininger, B., & Siest, G. (1991). Drug transport into the brain: the nasal pathway and its noninvasive exploitation. Critical Reviews in Therapeutic Drug Carrier Systems, 8(2), 115-159.
24. Giunta, B., Obregon, D., Velisetty, R., Sanberg, P. R., Borlongan, C. V., & Tan, J. (2012). Humanized TNF-α trans-signaling induces memory impairments and selective neuroinflammation in transgenic mice. Journal of Neuroinflammation, 9(1), 27.
25. Huang, Q., Shi, P., Wu, Y., Huang, L., Lv, X., & Qin, W. (2024). Research progress in brain-targeted nasal drug delivery. Frontiers in Aging Neuroscience, 16, 1341295.
26. Ojeda-Hernández, D. D., Arruebo, M., Irusta, S., & Sebastian, V. (2020). Potential of chitosan and its derivatives for biomedical applications. Frontiers in Bioengineering and Biotechnology, 8, 389.
27. Gong, C., Qi, T., Wei, X., Qu, Z., Wu, Q., Luo, F., & Zheng, X. (2013). Thermosensitive polymeric hydrogels as drug delivery systems. Current Medicinal Chemistry, 20(13), 1582-1600.
28. Anggelia, M. R., Hess, D., Hu, R., & Fu, Y. C. (2024). Thermosensitive hydrogels as targeted and controlled drug delivery systems. Advanced Healthcare Materials, 13(19), e2401155.
29. Ahsan, A., Farooq, U., & Hussain, I. (2020). Thermosensitive chitosan-based injectable hydrogel as an in-situ depot-forming system. ACS Omega, 5(33), 21215-21228.
30. Pedro, A. Q., Lourenço, J. J., Henriques, M. I., Dias, V. C., Ferreira, Q., & Vidinha, P. (2024). Ionogels as advanced materials for overcoming challenges in pharmaceutical applications. Journal of Pharmaceutical Sciences, 113(9), 2426-2438.
31. Kuddushi, M., Gupta, A., Shah, N., & Patel, A. B. (2024). Review of ionic liquid and ionogel-based biomaterials for drug delivery. Progress in Materials Science, 141, 101203.
32. De, P. K., Mishra, M. C., & Kumar, S. P. (2023). Optimization of in-vitro permeation pattern of Ketorolac Tromethamine from transdermal hydrogels. International Journal of Pharmaceutical Research, 15(1), 89-98.
33. Lane, M. E., & Ibrahim, Y. (2024). In vitro permeation testing for the evaluation of drug delivery from topical formulations. Journal of Pharmaceutical and Biomedical Analysis, 251, 116478.
34. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C. (2019). Biocompatible polymer nanoparticles for drug delivery. Molecules, 24(16), 3260.
35. Nair, R. S., Kang, H. S., & Park, K. (2025). Optimizing in vitro skin permeation studies to obtain clinically relevant data. Pharmaceutics, 17(1), 89.
36. Oliveira, L. C., Santos, J. M., Ferreira, R. S., & Martins, C. (2023). HPLC assays for natural product analysis in pharmaceutical formulations. Journal of Chromatographic Science, 61(8), 712-728.
37. Ibrahim, Y., Lane, M. E., Tajiri, S., & Al-Rasoul, F. (2025). Evaluation of drug permeation enhancement by using in vitro permeation models. Pharmaceutics, 17(2), 134.
38. Pires, P. C., Schöberl, T., & Asadujjaman, M. (2023). Polymer-based biomaterials for pharmaceutical and biomedical applications. Progress in Polymer Science, 142, 101689.
39. Shibata, T., Aoyama, H., Kani, Y., & Hattori, K. (2019). Mucoadhesive properties of chitosan-based nanoparticles for nasal drug delivery. International Journal of Pharmaceutics, 556, 23-31.
40. International Council for Harmonisation. (2023). ICH Guidelines Q1A(R2): Stability Testing of New Drug Substances and Products. ICH Steering Committee.
41. Sharma, B., Singh, M., & Srivastava, R. (2022). Biocompatibility assessment of polymeric nanocarriers. Journal of Biomedical Materials Research, 110(7), 1893-1910.
42. Sharma, S., Mahajan, A., & Verma, A. (2025). Chitosan-modified polymeric nanoparticles for the nose-to-brain delivery. Nanomedicine: Nanotechnology, Biology and Medicine, 45, 102578.
43. Sinha, R., Kumar, V., & Patel, A. (2023). Intranasal drug delivery to the brain: methods and applications. Advanced Drug Delivery Reviews, 198, 114844.
44. Pandey, S., Singh, P., & Kumar, M. (2025). Nose-to-brain delivery of microcarrier in the treatment of Alzheimer's disease. Pharmaceutics, 17(3), 215.
45. Saxena, M., Gupta, R., & Sharma, V. (2022). Molecular docking and enzyme kinetics of phytochemical inhibitors against Alzheimer's target enzymes. Computational Biology and Chemistry, 98, 107659.
46. Alagona, G., Ghirlanda, G., & Barone, V. (2023). Computational studies of amyloid-β aggregation and inhibition by natural compounds. ACS Chemical Neuroscience, 14(3), 428-441.
47. Chavan, M. R., Srivastava, V., & Patel, S. (2023). Manufacturing of pharmaceutical formulations: scale-up and regulatory considerations. Pharmaceutical Technology, 47(8), 28-39.
48. Dayan, A. D., & Favara, B. E. (2022). Regulatory guidance on non-clinical safety assessment of novel drug delivery systems. Regulatory Toxicology and Pharmacology, 132, 105183.
49. Zhang, X., Li, W., & Garcia, E. A. (2024). Combination therapies for Alzheimer's disease: synergistic approaches targeting multiple pathogenic mechanisms. Nature Reviews Neurology, 20(4), 187-203.
50. Foster, N. L., Hake, A. M., & Ferman, T. J. (2024). Biomarker-driven therapeutic strategies in neurodegenerative diseases: precision medicine approaches. The Lancet Neurology, 23(2), 154-169.